• Contains 30 mcg ethinylestradiol and 150 mcg levonorgestrel, exactly the same active ingredients as Ovranette® 1,2
  • Indicated for the prevention of pregnancy in women who elect to use oral contraception
  • Side effects may include mood changes and depression.
  • Causes changes in the endometrium and cervical mucus1,2
  • Reliable, highly effective and well tolerated oral contraceptive when taken correctly1
  • OVREENA® has a Pearl Index of 0.44
  • OVREENA® is GMS Reimbursed

OVREENA®  is suitable for use in the following patient groups:5,6

  • Women on the GMS reimbursement scheme
  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women ≥6 months postpartum if fully breast feeding
  • Women ≥6 weeks postpartum if not breast feeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis


1. Ovreena® SPC
2. Ovranette® SPC
available at www.medicines.ie
3. MIMS Ireland (August 2017) ‘Contraception’ MPI Media Ltd, Dublin.
4. Faculty of Sexual and Reproductive Health Care (FSRH). First Prescription of Combined Oral Contraception. Clinical Effectiveness Unit July 2006 (Updated January 2007) London: FSRH, 2007.
5. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.
6. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update

IE/OCS/0817/0058e Date of preparation: April 2019